Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Other Non-Current Liabilities fell 977.89% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 977.89%. This contributed to the annual value of $37.7 million for FY2024, which is 548.62% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Other Non-Current Liabilities of $43.9 million as of Q3 2025, which was down 977.89% from $40.9 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' Other Non-Current Liabilities' 5-year high stood at $76.7 million during Q4 2021, with a 5-year trough of $8.2 million in Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $42.7 million (2024), whereas its average is $42.7 million.
  • In the last 5 years, Insight Molecular Diagnostics' Other Non-Current Liabilities surged by 97698.03% in 2021 and then crashed by 8454.7% in 2023.
  • Insight Molecular Diagnostics' Other Non-Current Liabilities (Quarter) stood at $76.7 million in 2021, then plummeted by 40.45% to $45.7 million in 2022, then dropped by 12.62% to $39.9 million in 2023, then decreased by 5.49% to $37.7 million in 2024, then grew by 16.53% to $43.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $43.9 million for Q3 2025, versus $40.9 million for Q2 2025 and $38.4 million for Q1 2025.